Get started
Author

Louise Ainley

Observed names: Ainley, L, L. Ainley, Louise I. Ainley
ORCID: 0000-0003-0630-7065
Observed ORCID: 0000-0003-0630-7065
OpenAlex ID: A5080334692
Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma (PANGEA): a retrospective, multicohort study
2023 · Annie Cowan, Federico Ferrari, et al. · The Lancet Haematology · 85
PDF
Haematology patients and the risk of transfusion transmitted infection
2018 · Louise I. Ainley, Patricia E Hewitt · British Journal of Haematology · 33
PDF
Serological response to the BNT162b2 mRNA or ChAdOx1 nCoV‐19 COVID‐19 vaccine after first and second doses in patients with plasma cell disorders: influence of host and disease factors
2021 · Wei Yee Chan, Lara Howells, et al. · British Journal of Haematology · 12
PDF
Under-representation of ethnic minorities in early phase clinical trials for multiple myeloma
2022 · Samir Asher, Aikaterini Kazantzi, et al. · Haematologica · 11
PDF
Tumour-intrinsic features shape T cell differentiation through precursor to symptomatic multiple myeloma
2026 · Kane A. Foster, Elise Rees, et al. · Nature Communications · 9
Enhanced dynamic risk stratification of smoldering multiple myeloma
2026 · Floris Chabrun, Daniel E. Schwartz, et al. · Nature Medicine · 7
PDF
Prevalence of maternal alloantibodies in a large teaching hospital and their impact on outcomes of fetuses/neonates
2017 · L. Ainley, J. R. Jardim, et al. · Transfusion Medicine · 7
Tumour-intrinsic features shape T-cell differentiation through myeloma disease evolution
2024 · Kane A. Foster, Elise Rees, et al. · medRxiv · 4
Adaptation of a multiple myeloma minimal residual disease multicolor flow cytometry assay for real‐world practice
2022 · Annabel McMillan, Thien‐An Tran, et al. · Cytometry Part B Clinical Cytometry · 4
Applying current smouldering myeloma risk models to a UK single‐centre cohort and clinical features at progression
2021 · Louise Ainley, Marquita Camilleri, et al. · British Journal of Haematology · 3
PDF
Development of antibody response to SARS‐CoV‐2 following asymptomatic infection in patients with plasma cell disorders on immunomodulatory therapy
2021 · Wei Yee Chan, Emilie Sanchez, et al. · British Journal of Haematology · 3
PDF
DT‐PACE/ESHAP chemotherapy regimens as salvage therapy for multiple myeloma prior to autologous stem cell transplantation
2020 · Louise Ainley, Selina J. Chavda, et al. · British Journal of Haematology · 3
Treatment of Concurrent Minimal Change Disease and Epstein Barr Virus–Driven Post-transplant Lymphoproliferative Disorder With Rituximab Following Hematopoietic Stem Cell Transplantation
2020 · Louise Ainley, Steven Law, et al. · Kidney International Reports · 3
PDF
Single-cell profiling of human bone marrow reveals multiple myeloma progression is accompanied by an increase in CD56 bright bone marrow resident NK cells
2025 · Elise Rees, Isabella Sodi, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
Improved Risk Stratification of Smoldering Multiple Myeloma (SMM) Using Trajectory Data in the Pangea 2.0 Model: A Multicenter Study in 1,431 Participants
2024 · Floris Chabrun, Daniel Schwartz, et al. · Blood · 2
PDF
Tumour-Intrinsic Features Shape T-Cell Differentiation through Myeloma Disease Evolution
2024 · Kane A Foster, Elise Rees, et al. · Blood · 2
OAB-024: T cell differentiation in the bone marrow during disease evolution: insights from COSMOS and integrative analysis of 317,000 single-cell transcriptomes
2022 · Kane Foster, Elise Rees, et al. · Clinical Lymphoma Myeloma & Leukemia · 2
PA-114 Co-opting the BAFF-APRIL Pathway in Smouldering Myeloma (SMM) to Fuel Disease Progression
2026 · Elise Rees, Amatta Mirandari, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-283 Longitudinal Analysis of TCR Repertoire in Smouldering Multiple Myeloma Reveals Relative Expansion of Shared-Sequence TCR Clusters Compared to Healthy Donors
2026 · Annabel Laidler, Matthew Cowley, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-219 Health-Related Quality of Life (HRQoL) Is Influenced by Clinical Features Rather Than Genetic Risk in Newly Diagnosed Myeloma Patients: Results from the UK Myeloma Research Alliance (MRA) RADAR Trial
2026 · Catherine S.Y. Lecat, Daniel Hughes, et al. · Clinical Lymphoma Myeloma & Leukemia
OA-14 Clinically Significant Bone Disease Is Uncommon in Smouldering Myeloma Progressors Monitored With Modern Imaging: Findings From the Prospective Multi-Centre UK MRA COSMOS Study
2026 · Louise Ainley, Daniel Hughes, et al. · Clinical Lymphoma Myeloma & Leukemia
PA-208 Function Tracks Disease, Psychology Tracks Diagnosis: Dissociable Patient-Reported Burden in Smouldering Myeloma: Initial Report from the UK MRA COSMOS Study
2026 · Daniel Hughes, Catherine S.Y. Lecat, et al. · Clinical Lymphoma Myeloma & Leukemia
Immune clues to infection risk in myeloma
2026 · Louise Ainley, Kwee Yong · Blood
Long-read RNA sequencing of first multiple myeloma patient cohort reveals landscape of variant expression in newly diagnosed patients from the UKMRA RADAR trial
2025 · Bethan Hudson-Lund, Anandagopal Srinivasan, et al. · Blood
Comparing Smouldering Myeloma High-Risk and Evolving Phenotype Definitions in the Prospective, Nationwide UK Cosmos Study
2025 · Daniel Hughes, Louise Ainley, et al. · Clinical Lymphoma Myeloma & Leukemia
Works count: 38
Citation count: 192
H-index: 7
I10-index: 4
Year
Topic
Type